As the heat of the climate crisis continues to rise, WBR Insights - Supply Chain has produced its first annual sustainability report by surveying 150 senior life sciences executives across Europe to uncover their sustainability challenges and solutions.
This exclusive report explores pharmaceutical leaders’ 2023 priorities, focusing on environmental impact reduction and goal fulfillment.
Curious how the pharma industry can operationalize its sustainability goals and achieve traction in decarbonization? Then have a look at the 2023 Sustainability Report by LogiPharma and WBR Insights and the contributions from our colleagues Dr. Stefan Kahl and Clive Geldard.
Access this insightful report and uncover the latest trends, strategies, and innovations in sustainable supply chain management. Let’s make a positive impact together!
Discover the strategies that top-performing companies are employing to develop world-class, performance-driven organizations.
EFESO helps drone manufacturers build future-ready factories, modular, scalable, and digitalized, to meet fast-growing defense market demand.
The UK off-highway vehicle sector is experiencing rapid growth, driven by electrification, sustainability, and infrastructure expansion, presenting significant opportunities for manufacturers.
Aerospace and defense firms need agile, value-focused capital investment strategies to manage complexity and maximize performance.
Chemical supply chains face mounting cost pressures and geopolitical uncertainty requiring strategic footprint optimization and sustainability integration.
UK food, beverage, and consumer goods sectors face rising labor costs due to increased NI contributions and minimum wage, impacting profitability and competitiveness.
Discover how EFESO And SEAM empowered European abrasives manufacturers to measure and reduce their carbon footprint
An interview with BBC StoryWorks on how leaders can remain effective in times of uncertainty by combining a clear sense of purpose with true operational agility.
Transform sustainability from compliance burden into measurable value creation for private equity portfolio companies.
